Biotech Values

[vinmantoo]

I would imagine newer inhibitors of the main protease could tackle some paxlovid resistance but the inevitable development of resistance over time is probably why companies like enta are also looking at other targets now

I agree completely. Add in that more and hopefully better protease inhibitors as well as inhibitors to other targets will likely have good efficacy to newer Covid variants as well as to related coronaviruses.